Streetbeat News

VVOS

Vivos Therapeutics, Inc.

Industry

Medical - Devices

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.

Open

3.00

Mkt cap

15M

Volume

273K

High

3.27

P/E Ratio

-0.64

52-wk high

48.79

Low

3.00

Div yield

N/A

52-wk low

1.91

Vivos Therapeutics, Inc. held its Q3 2024 earnings call, discussing financial results and company performance. Key participants included CEO Kirk Huntsman and CFO Brad Amman.

Portfolio Pulse from

November 15, 2024 | 4:45 am

Vivos Therapeutics has received approval from the American Medical Association for new CPT medical codes for its Vivos CARE oral devices, effective January 1, 2025. This approval is expected to enhance insurance coverage and accessibility for their sleep apnea treatments, potentially driving revenue growth.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 11:35 am

U.S. stocks rose with the S&P 500, Dow, and NASDAQ all gaining. Darden Restaurants missed earnings estimates, while Mobileye Global shares surged after Intel decided not to divest its interest. Edgewise Therapeutics and Signing Day Sports saw significant stock price increases.

Portfolio Pulse from Avi Kapoor

September 19, 2024 | 6:57 pm

U.S. stocks rose significantly, with the Dow Jones up over 500 points. FactSet Research Systems reported strong earnings, beating expectations. Edgewise Therapeutics, Signing Day Sports, and Mobileye Global saw notable stock increases, while Haoxi Health Technology, Progyny, and Vivos Therapeutics experienced declines.

Portfolio Pulse from Avi Kapoor

September 19, 2024 | 4:39 pm

Vivos Therapeutics (NASDAQ:VVOS) shares fell 26.1% to $3.05 after announcing a $4.3 million registered offering of 1.36 million shares at $3.15 each. The offering, expected to close on September 20, will be managed by H.C. Wainwright & Co. and aims to raise funds for working capital and general corporate purposes.

Portfolio Pulse from Henry Khederian

September 19, 2024 | 2:37 pm

U.S. stocks surged with the Nasdaq Composite rising over 400 points, driven by a drop in jobless claims and strong performance in the information technology sector. Telesis Bio, Signing Day Sports, and Zeo Energy saw significant stock price increases, while Haoxi Health Technology, Progyny, and Vivos Therapeutics experienced declines.

Portfolio Pulse from Avi Kapoor

September 19, 2024 | 1:40 pm

Vivos Therapeutics shares declined following the announcement of a $4.3 million registered offering of 1.36 million shares at $3.15 each.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 1:19 pm

Vivos Therapeutics has announced a registered offering of $4.3 million, selling 1.36 million shares at $3.15 per share.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 11:13 am

The stock market declined after the Federal Reserve cut interest rates by 0.5%. Nvidia, T-Mobile US, Vivos Therapeutics, SoFi Technologies, and Tesla were notable stocks. Nvidia is considering an acquisition, T-Mobile announced partnerships, Vivos received FDA clearance, SoFi saw heavy trading, and Tesla rose slightly.

Portfolio Pulse from Benzinga Neuro

September 19, 2024 | 3:09 am

Vivos Therapeutics has received FDA 510(k) clearance for its DNA appliance, designed to treat pediatric obstructive sleep apnea (OSA) and snoring. This approval allows Vivos to enter the pediatric market, potentially capturing significant market share. The device is non-invasive and effective, with clinical trials showing significant improvements in sleep-related symptoms. Vivos plans to quickly integrate this into its marketing model to scale revenue.

Portfolio Pulse from Vandana Singh

September 18, 2024 | 2:05 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.